| 1 | ALS | Interventional | Perpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen G: DNL343) | Study is ongoing/Recruitment completed | Click here |
| 2 | ALS | Interventional | Perpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen F: ABBV-CLS-7262) | Study is ongoing/Recruitment completed | Click here |
| 3 | ALS | Interventional | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks, Followed by an Open-Label Extension (ASTRALS) | Recruiting | Click here |
| 4 | ALS | Interventional | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination with Riluzole Versus Placebo in Combination with Riluzole in the Treatment of Patients Suffering from Amyotrophic Lateral Sclerosis (ALS) | Recruiting | Click here |
| 5 | ALS | Interventional | A Two-part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open Label Extension, Multicenter Study of the Efficacy and Safety of NurOwn in Participants with Amyotrophic Lateral Sclerosis | Not open for enrollment yet | [A link should be added here when available] |
| 6 | ALS | Interventional | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Phase 3 Trial to Compare the Efficacy and Safety of Masitinib in Combination with Standard of Care Versus Placebo in Combination with Standard of Care in the Treatment of Patients Suffering from Amyotrophic Lateral Sclerosis (ALS) | Not open for enrollment yet | [A link should be added here when available] |
| 7 | ALS | Non-Interventional | Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone | Recruiting | Click here |
| 8 | ALS | Non-Interventional | Cellular Reprogramming to Study Neurodegenerative Diseases, Including ALS and FTD, Using Patient-Derived Induced Pluripotent Stem Cells (Principal Investigator: Dr. Justin Ichida) | Active | [A link should be added here when available] |
| 9 | Myasthenia Gravis | Interventional | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis | Recruiting | Click here |
| 10 | Myasthenia Gravis | Interventional | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis (NIMBLE) | Recruiting | Click here |
| 11 | CIDP | Interventional | A Phase 3, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Riliprubart in Participants with Refractory Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | Click here |
| 12 | CIDP | Interventional | A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Active, not recruiting | Click here |
| 13 | CIDP | Interventional | A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (VITALIZE study) | Active, not recruiting | Click here |
| 14 | IIM | Interventional | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | Recruiting | Click here |
| 15 | IBM | Interventional | An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis | Active, not recruiting | Click here |
| 16 | IBM | Interventional | A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis | Active, not recruiting | Click here |
